OBJECTIVE: The natural history of the supratentorial low-grade glioma (LGG) of the adult is variable, and its malignant transformation is hardly predictable. Because positron emission tomography with [18F]fluoro-2-deoxy-D-glucose (FDG) has prognostic value in high-grade gliomas, this study was designed to search for a possible relationship between glucose metabolism and risk of malignant evolution in LGGs. METHODS: Positron emission tomography with FDG was performed in 28 patients with LGGs (22 at the time of diagnosis and 6 after the diagnosis). A metabolic grading system based on the visual inspection of the positron emission tomographic images was used. RESULTS: In 19 patients, no area of FDG uptake higher than in the white matter was detected (metabolic Grade 1). All of those patients were alive at the end of the follow-up period. Only one of the patients presented a histological modification 7 months after the diagnosis. Nine patients presented areas of increased FDG uptake (metabolic Grade 2 or 3). Those areas were found in the tumor area in eight patients and in an area of radionecrosis in one. Of the nine patients with FDG "hot spots," six died, two had recurrence but were alive at the end of the follow-up period, and the patient with radionecrosis had no signs of recurrence. CONCLUSIONS: The presence of areas of increased FDG uptake in a histologically proven LGG predicts, in most cases, a deleterious evolution. This metabolic feature, detectable with a noninvasive procedure, may provide a clue to cellular changes, announcing malignant transformation in a tumor that retains the histological features of an LGG. Protocols with aggressive therapeutic strategies in this situation should be considered for evaluation.
OBJECTIVE: The natural history of the supratentorial low-grade glioma (LGG) of the adult is variable, and its malignant transformation is hardly predictable. Because positron emission tomography with [18F]fluoro-2-deoxy-D-glucose (FDG) has prognostic value in high-grade gliomas, this study was designed to search for a possible relationship between glucose metabolism and risk of malignant evolution in LGGs. METHODS: Positron emission tomography with FDG was performed in 28 patients with LGGs (22 at the time of diagnosis and 6 after the diagnosis). A metabolic grading system based on the visual inspection of the positron emission tomographic images was used. RESULTS: In 19 patients, no area of FDG uptake higher than in the white matter was detected (metabolic Grade 1). All of those patients were alive at the end of the follow-up period. Only one of the patients presented a histological modification 7 months after the diagnosis. Nine patients presented areas of increased FDG uptake (metabolic Grade 2 or 3). Those areas were found in the tumor area in eight patients and in an area of radionecrosis in one. Of the nine patients with FDG "hot spots," six died, two had recurrence but were alive at the end of the follow-up period, and the patient with radionecrosis had no signs of recurrence. CONCLUSIONS: The presence of areas of increased FDG uptake in a histologically proven LGG predicts, in most cases, a deleterious evolution. This metabolic feature, detectable with a noninvasive procedure, may provide a clue to cellular changes, announcing malignant transformation in a tumor that retains the histological features of an LGG. Protocols with aggressive therapeutic strategies in this situation should be considered for evaluation.
Authors: M V Padma; S Said; M Jacobs; D R Hwang; K Dunigan; M Satter; B Christian; J Ruppert; T Bernstein; G Kraus; J C Mantil Journal: J Neurooncol Date: 2003-09 Impact factor: 4.130
Authors: D Winkler; G Strauss; S Hesse; A Goldammer; M Hund-Georgiadis; A Richter; O Sabri; T Kahn; J Meixensberger Journal: Radiologe Date: 2004-07 Impact factor: 0.635
Authors: Katherine A Zukotynski; Frederic H Fahey; Mehmet Kocak; Abass Alavi; Terence Z Wong; S Ted Treves; Barry L Shulkin; Daphne A Haas-Kogan; Jeffrey R Geyer; Sridhar Vajapeyam; James M Boyett; Larry E Kun; Tina Young Poussaint Journal: J Nucl Med Date: 2011-01-13 Impact factor: 10.057
Authors: F Giammarile; L E Cinotti; A Jouvet; J M Ramackers; G Saint Pierre; P Thiesse; E Jouanneau; J Guyotat; I Pelissou-Guyotat; A Setiey; J Honnorat; D Le Bars; D Frappaz Journal: J Neurooncol Date: 2004-07 Impact factor: 4.130
Authors: Gethin Williams; Frederic H Fahey; S Ted Treves; Mehmet Kocak; Ian F Pollack; James M Boyett; Larry E Kun; Tina Young Poussaint Journal: Eur J Nucl Med Mol Imaging Date: 2008-04-19 Impact factor: 9.236